Description

Overview

Survodutide (BI 456906) is an investigational dual agonist designed to activate both GLP-1 and glucagon receptors. The GLP-1 component targets incretin, appetite, and glucose-regulation pathways, while glucagon-receptor activity is being studied for effects on energy expenditure and hepatic lipid metabolism. Human clinical programs have evaluated obesity and metabolic dysfunction-associated steatohepatitis/liver-fat outcomes. It remains a clinical-development compound.

How It Works

GLP-1 receptor signaling: Influences satiety, glucose-dependent insulin signaling, and gastrointestinal pathways.
Glucagon receptor signaling: Research investigates energy expenditure, lipid oxidation, and hepatic metabolism.
Dual-pathway integration: The compound is designed to balance two receptor systems for complementary metabolic effects.

Research Areas

Obesity research
Metabolic liver disease
Hepatic fat metabolism
Glycemic and cardiometabolic endpoints

Research / Study Context

Phase 2 obesity research: Human trials evaluated body-weight change, metabolic markers, tolerability, and dose-response.
MASH/liver research: Randomized trials have evaluated liver histology, liver fat, fibrosis-related endpoints, and metabolic outcomes.

Key Research Findings

Clinical studies demonstrate strong biologic activity in obesity and liver-metabolism endpoints.
Gastrointestinal adverse effects are common in GLP-1-based research.
Survodutide remains investigational and is not an approved therapy.